{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:08:00Z","timestamp":1788606480783,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13300-025-01791-y","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:19:09Z","timestamp":1757589549000},"page":"2073-2082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evidence-Based Guidelines for Intravitreal Anti-VEGF Therapy for Diabetic Retinopathy in Chronic Kidney Disease"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-5131","authenticated-orcid":false,"given":"Sourabh","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Hada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devesh","family":"Kumawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Bhushan","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"5","key":"1791_CR1","first-page":"1098","volume":"13","author":"TA Bahr","year":"2023","unstructured":"Bahr TA, Bakri SJ. Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy. Life (Basel). 2023;13(5):1098.","journal-title":"Life (Basel)"},{"issue":"12","key":"1791_CR2","first-page":"2826","volume":"71","author":"DE Kurian","year":"2021","unstructured":"Kurian DE, Kalra S, Kapoor N. Screening for diabetic retinopathy in primary care: future prospects in low-middle income countries. J Pak Med Assoc. 2021;71(12):2826\u20137.","journal-title":"J Pak Med Assoc"},{"issue":"2","key":"1791_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3904\/kjim.2003.18.2.65","volume":"18","author":"BS Kim","year":"2003","unstructured":"Kim BS, Goligorsky MS. Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease. Korean J Intern Med. 2003;18(2):65\u201375.","journal-title":"Korean J Intern Med"},{"issue":"3","key":"1791_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","volume":"96","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572\u201380.","journal-title":"Kidney Int"},{"issue":"5","key":"1791_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.ekir.2024.02.003","volume":"9","author":"M Rivero","year":"2024","unstructured":"Rivero M, Fern\u00e1ndez-Vidal M, Sandino J, et al. Effect of intravitreal anti-endothelial growth factor agents on renal function in patients with diabetes mellitus. Kidney Int Rep. 2024;9(5):1397\u2013405.","journal-title":"Kidney Int Rep"},{"issue":"24","key":"1791_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Escudier B, Lhomme C. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore). 2014;93(24):333\u20139.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"1791_CR7","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847\u201358.","journal-title":"Retina"},{"issue":"6","key":"1791_CR8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond). 2018;32(6):1010\u201320.","journal-title":"Eye (Lond)"},{"key":"1791_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","volume":"13","author":"M Shye","year":"2020","unstructured":"Shye M, Hanna RM, Patel SS, et al. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. Clin Kidney J. 2020;13:969\u201380.","journal-title":"Clin Kidney J"},{"key":"1791_CR10","first-page":"421","volume":"34","author":"MA P\u00e9rez-Valdivia","year":"2014","unstructured":"P\u00e9rez-Valdivia MA, L\u00f3pez-Mendoza M, Toro-Prieto FJ, et al. Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab. Nefrologia. 2014;34:421\u20132.","journal-title":"Nefrologia"},{"key":"1791_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/ped.12017","volume":"55","author":"T Sato","year":"2013","unstructured":"Sato T, Kawasaki Y, Waragai T, et al. Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab: MCNS relapse and intravitreal bevacizumab. Pediatr Int. 2013;55:46\u20138.","journal-title":"Pediatr Int"},{"key":"1791_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ckj\/sfy060","volume":"12","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Lopez EA, Hasnain H, et al. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2019;12:92\u2013100.","journal-title":"Clin Kidney J"},{"key":"1791_CR13","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1097\/TP.0000000000000750","volume":"99","author":"W Cheungpasitporn","year":"2015","unstructured":"Cheungpasitporn W, Chebib FT, Cornell LD, et al. Intravitreal antivascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts. Transplantation. 2015;99:2382\u20136.","journal-title":"Transplantation"},{"issue":"8","key":"1791_CR14","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21(8):1381\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"1791_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ndt\/gfn657","volume":"24","author":"G Bollee","year":"2009","unstructured":"Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24:682\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"1791_CR16","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129\u201336.","journal-title":"N Engl J Med"},{"key":"1791_CR17","first-page":"600","volume":"56","author":"K Haruhara","year":"2014","unstructured":"Haruhara K, Tsuboi N, Nakao M, et al. A case of glomerulopathy associated with the vascular endothelial growth factor inhibitor bevacizumab. Nihon Jinzo Gakkai Shi. 2014;56:600\u20135 (in Japanese).","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"1791_CR18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","volume":"22","author":"H Izzedine","year":"2007","unstructured":"Izzedine H, Brocheriou I, Deray G, et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant. 2007;22:1481\u20132.","journal-title":"Nephrol Dial Transplant"},{"key":"1791_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.15171\/jnp.2017.23","volume":"6","author":"G Khneizer","year":"2017","unstructured":"Khneizer G, Al-Taee A, Bastani B. Self-limited membranous nephropathy after intravitreal nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration. J Nephropathol. 2017;6:134\u20137.","journal-title":"J Nephropathol"},{"key":"1791_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/2474126418815823","author":"JDJ Kenworthy","year":"2018","unstructured":"Kenworthy JDJ, Chandra V, Clark B, Desmond M. Worsening proteinuria following intravitreal anti-VEGF therapy for diabetic macular edema. J Vitreo-Retinal Dis. 2018. https:\/\/doi.org\/10.1177\/2474126418815823.","journal-title":"J Vitreo-Retinal Dis"},{"key":"1791_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113701","volume":"9","author":"A Tschulakow","year":"2014","unstructured":"Tschulakow A, Christner S, Julien S, et al. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS ONE. 2014;9:e113701.","journal-title":"PLoS ONE"},{"key":"1791_CR22","first-page":"4629","volume":"32","author":"T Evans","year":"2012","unstructured":"Evans T. Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC. Anticancer Res. 2012;32:4629\u201338.","journal-title":"Anticancer Res"},{"key":"1791_CR23","first-page":"3465","volume":"27","author":"A Pande","year":"2007","unstructured":"Pande A, Lombardo J, Spangenthal E, et al. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007;27:3465\u201370.","journal-title":"Anticancer Res"},{"key":"1791_CR24","first-page":"435","volume":"54","author":"D Risimic","year":"2013","unstructured":"Risimic D, Milenkovic S, Nikolic D, et al. Influence of intravitreal injection of bevacizumab on systemic blood pressure changes in patients with exudative form of age-related macular degeneration. Hellenic J Cardiol. 2013;54:435\u201340.","journal-title":"Hellenic J Cardiol"},{"key":"1791_CR25","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/eye.2008.360","volume":"23","author":"R Rasier","year":"2009","unstructured":"Rasier R, Artunay O, Yuzbasioglu E, et al. The effect of intravitreal bevacizumab (Avastin) administration on systemic hypertension. Eye (Lond). 2009;23:1714\u20138.","journal-title":"Eye (Lond)"},{"key":"1791_CR26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/IAE.0b013e3181b21056","volume":"29","author":"K Lee","year":"2009","unstructured":"Lee K, Yang H, Lim H, et al. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina. 2009;29:1409\u201317.","journal-title":"Retina"},{"key":"1791_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20907033","volume":"8","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Abdelnour L, Hasnain H, Selamet U, Kurtz I. Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab. SAGE Open Med Case Rep. 2020;8:2050313X20907033.","journal-title":"SAGE Open Med Case Rep"},{"issue":"8","key":"1791_CR28","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.4103\/IJO.IJO_44_23","volume":"71","author":"MP Del Cura","year":"2023","unstructured":"Del Cura MP, Carball\u00e9s MJC, Sastre-Ib\u00e1\u00f1ez M. Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice. Indian J Ophthalmol. 2023;71(8):3091\u20134.","journal-title":"Indian J Ophthalmol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01791-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01791-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01791-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:10:02Z","timestamp":1761948602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01791-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01791-y","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Sourabh Sharma, Himanshu Verma, Nitin Kapoor, Lakshmi Nagendra, AG Unnikrishnan, Sudeep Prakash, Manisha Sahay, Pradeep Venkatesh, Maya Hada, Devesh Kumawat, Sree Bhushan Raju and Radhika Tandon have nothing to disclose. Sanjay Kalra is a member of the Editorial Board of\n                      Diabetes Therapy\n                      . Sanjay Kalra was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}